Randomized Study of Weekly Erythropoietin Dosing in Preterm Infants

• Status: Completed
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Preterm infants are a risk for multiple transfusions, and the administration of human recombinant erythropoietin (Epo) has been shown to decrease transfusion requirements. Dosing usually occurs three times a week, but extended dosing schedules have been successful in adults. The investigators assessed weekly Epo dosing in preterm infants compared to standard three times weekly dosing.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of New Mexico
• Collaborator: National Center for Research Resources (NCRR)
• Treatments: Epoetin Alfa

Criteria

Inclusion Criteria:

• < or = 1,500 grams

• < or = 32 weeks gestation

• > or = 7 days of age

• informed consent obtained

Exclusion Criteria:

• hemolytic disease

• hypertension

• seizures

• thromboses

• major malformation